506U78 in Treating Patients With Refractory Hematologic Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Collaborator: Children's Cancer Group
• Treatments: Cortisol succinate; Cytarabine; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Methotrexate

Criteria

Inclusion Criteria:

• Refractory or recurrent acute lymphocytic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) with bone marrow involvement (T-cell disease only)

• Isolated CNS relapse not eligible

• Performance status - Karnofsky 50-100%

• At least 8 weeks

• Bilirubin no greater than 1.5 mg/dL

• SGPT less than 5 times normal

• Creatinine normal for age

• Creatinine clearance or GFR at least 60 mL/min/1.73m2

• No severe uncontrolled infection

• No concurrent biologic therapy

• Recovered from toxic effects

• At least 6 weeks from administration of nitrosoureas

• No concurrent endocrine therapy

• At least 6 weeks from administration of craniospinal or hemi pelvic radiotherapy